(NASDAQ: GRI) Gri Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.77%.
Gri Bio's earnings in 2026 is -$9,659,000.On average, 3 Wall Street analysts forecast GRI's earnings for 2026 to be -$10,532,046, with the lowest GRI earnings forecast at -$10,990,475, and the highest GRI earnings forecast at -$10,122,806. On average, 3 Wall Street analysts forecast GRI's earnings for 2027 to be -$34,013,982, with the lowest GRI earnings forecast at -$55,702,210, and the highest GRI earnings forecast at -$11,040,974.
In 2028, GRI is forecast to generate -$44,159,523 in earnings, with the lowest earnings forecast at -$42,847,854 and the highest earnings forecast at -$45,908,415.